Total Payments
$4,879
2024 Payments
$1,702
Companies
43
Transactions
211
Medicare Patients
4,720
Medicare Billing
$484,523
Payment Breakdown by Category
Food & Beverage$2,779 (57.0%)
Other$1,632 (33.5%)
Education$468.06 (9.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,779 | 164 | 57.0% |
| Long term medical supply or device loan | $1,632 | 19 | 33.5% |
| Education | $468.06 | 28 | 9.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,136 | 51 | $0 (2024) |
| PFIZER INC. | $682.28 | 44 | $0 (2024) |
| Merck Sharp & Dohme LLC | $212.20 | 12 | $0 (2024) |
| ABBVIE INC. | $132.46 | 8 | $0 (2024) |
| Incyte Corporation | $121.55 | 7 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $112.38 | 7 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $110.41 | 6 | $0 (2024) |
| Astellas Pharma US Inc | $106.36 | 7 | $0 (2024) |
| Genentech USA, Inc. | $89.03 | 6 | $0 (2022) |
| GENZYME CORPORATION | $80.18 | 5 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,702 | 51 | Novartis Pharmaceuticals Corporation ($1,095) |
| 2023 | $1,295 | 65 | Novartis Pharmaceuticals Corporation ($430.13) |
| 2022 | $1,261 | 59 | Novartis Pharmaceuticals Corporation ($520.15) |
| 2021 | $125.18 | 8 | Novartis Pharmaceuticals Corporation ($54.28) |
| 2020 | $97.63 | 6 | Astellas Pharma US Inc ($18.62) |
| 2019 | $146.27 | 10 | Pharmacyclics LLC, An AbbVie Company ($35.19) |
| 2018 | $92.73 | 5 | Allergan Inc. ($24.72) |
| 2017 | $159.80 | 7 | Bayer HealthCare Pharmaceuticals Inc. ($64.55) |
All Payment Transactions
211 individual payment records from CMS Open Payments — Page 3 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX, COMIRNATY | Food and Beverage | In-kind items and services | $7.45 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: Immunology | ||||||
| 12/13/2023 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 12/07/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: Oncology | ||||||
| 12/04/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.34 | General |
| Category: ONCOLOGY | ||||||
| 11/29/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), PIQRAY | Food and Beverage | In-kind items and services | $10.59 | General |
| Category: Oncology | ||||||
| 11/28/2023 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/06/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.80 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: Oncology | ||||||
| 10/21/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.85 | General |
| 10/19/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $15.23 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 09/29/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: ONCOLOGY | ||||||
| 09/22/2023 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $15.70 | General |
| Category: Oncology | ||||||
| 09/13/2023 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $28.24 | General |
| Category: HORMONE THERAPY | ||||||
| 09/11/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $9.66 | General |
| Category: ONCOLOGY | ||||||
| 08/31/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: ONCOLOGY | ||||||
| 08/25/2023 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $16.18 | General |
| Category: Oncology | ||||||
| 08/18/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,250 | 3,613 | $294,136 | $131,237 |
| 2022 | 9 | 1,225 | 3,540 | $286,899 | $122,636 |
| 2021 | 11 | 1,169 | 3,121 | $267,942 | $127,532 |
| 2020 | 11 | 1,076 | 3,153 | $241,865 | $103,119 |
Total Patients
4,720
Total Services
13,427
Medicare Billing
$484,523
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 212 | 468 | $120,276 | $58,469 | 48.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 238 | 420 | $77,280 | $34,981 | 45.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 348 | 1,452 | $18,846 | $12,157 | 64.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 297 | 1,099 | $40,663 | $8,331 | 20.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 40 | 40 | $13,240 | $6,382 | 48.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 40 | 40 | $10,400 | $4,468 | 43.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 54 | $6,966 | $3,342 | 48.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 17 | $3,774 | $1,705 | 45.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 23 | $2,691 | $1,403 | 52.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 209 | 483 | $124,131 | $60,952 | 49.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 211 | 328 | $60,352 | $28,648 | 47.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 309 | 1,182 | $43,734 | $9,037 | 20.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 47 | 47 | $15,557 | $7,591 | 48.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 56 | 56 | $14,560 | $6,599 | 45.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 327 | 1,377 | $16,524 | $4,066 | 24.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 43 | 43 | $5,547 | $2,723 | 49.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 11 | $3,608 | $1,669 | 46.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 12 | 13 | $2,886 | $1,353 | 46.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 212 | 522 | $124,056 | $68,975 | 55.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 147 | 220 | $38,941 | $20,079 | 51.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 275 | 952 | $35,224 | $7,391 | 21.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 40 | 40 | $13,048 | $6,863 | 52.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 41 | 41 | $10,534 | $4,942 | 46.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 73 | 80 | $9,640 | $4,844 | 50.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 20 | 27 | $8,688 | $4,202 | 48.4% |
About Dr. Jordan Morton, MD
Dr. Jordan Morton, MD is a Hematology & Oncology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2011. The National Provider Identifier (NPI) number assigned to this provider is 1659665867.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jordan Morton, MD has received a total of $4,879 in payments from pharmaceutical and medical device companies, with $1,702 received in 2024. These payments were reported across 211 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($2,779).
As a Medicare-enrolled provider, Morton has provided services to 4,720 Medicare beneficiaries, totaling 13,427 services with total Medicare billing of $484,523. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Oklahoma City, OK
- Active Since 06/06/2011
- Last Updated 03/14/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1659665867
Products in Payments
- KISQALI (Drug) $1,417
- IBRANCE (Drug) $430.37
- KEYTRUDA (Biological) $212.20
- PROMACTA (Drug) $150.90
- ORGOVYX (Drug) $115.43
- VENCLEXTA (Drug) $113.87
- Onivyde (Drug) $112.38
- XTANDI (Drug) $104.79
- OPDIVO (Biological) $81.07
- MEKINIST (Drug) $77.30
- PLUVICTO (Drug) $75.04
- PADCEV (Biological) $74.87
- Xofigo (Drug) $64.55
- Padcev (Drug) $61.59
- Nplate (Biological) $58.28
- DARZALEX (Biological) $57.49
- Fabhalta (Drug) $56.18
- JAKAFI (Drug) $56.10
- MONJUVI (Drug) $55.89
- Imbruvica (Drug) $54.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oklahoma City
Robert Reynolds, Md, MD
Hematology & Oncology — Payments: $14,579
Hematology & Oncology $14,579
Philip Comp, Md, MD
Hematology & Oncology — Payments: $13,151
Hematology & Oncology $13,151
Dr. Charles Hollen, M.d, M.D
Hematology & Oncology — Payments: $12,135
Hematology & Oncology $12,135
Jennifer Holter-Chakrabarty, Md, MD
Hematology & Oncology — Payments: $11,994
Hematology & Oncology $11,994
Dr. Saadia Chohan, Md, MD
Hematology & Oncology — Payments: $11,197
Hematology & Oncology $11,197
Abby Bova, Md, MD
Hematology & Oncology — Payments: $5,791
Hematology & Oncology $5,791